BioNTech's cancer pipeline is bigger than its COVID-era reputation suggests, and the stock still trades below $100.
BioNTech SE American Depositary Share (BNTX) News
Latest headlines that mention BNTX, newest first · each headline opens the original publisher
- Last price
- $92.06
- Day change
- -3.35%
- Next earnings
- 2026-11-03 BMO
BNTX headlines
last 30 daysModerna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase.
The company is looking to prove it can achieve significant success outside the coronavirus market.
Investors buying this biotech stock now will get its pipeline essentially for free.
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.
Also mentioned with BNTX
30dHeadlines that tag both tickers
BNTX news alerts
Get an alert by email or push when a new headline mentions BNTX.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.